A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome
Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. A mu...
Saved in:
| Published in | BMC gastroenterology Vol. 13; no. 1; p. 45 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
07.03.2013
BioMed Central |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations.
A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS-Constipation or IBS-Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life.
179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12.
Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. UK TRIAL REGISTRATION: ISRCTN78863629. |
|---|---|
| AbstractList | Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations.
A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS-Constipation or IBS-Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life.
179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12.
Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. UK TRIAL REGISTRATION: ISRCTN78863629. BACKGROUND: Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. METHODS: A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS - Constipation or IBS - Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life. RESULTS: 179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12. CONCLUSIONS: Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. : UK Trial registration:ISRCTN78863629 Doc number: 45 Abstract Background: Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. Methods: A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS - Constipation or IBS - Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life. Results: 179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12. Conclusions: Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. UK Trial registration:ISRCTN78863629 Abstract Background Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. Methods A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS – Constipation or IBS – Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18–65 completed a pre-study diary. Eligible individuals were randomized to consume dairy ‘yoghurt’ products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life. Results 179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12. Conclusions Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. UK Trial registration ISRCTN78863629 Background Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. Methods A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS - Constipation or IBS - Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life. Results 179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12. Conclusions Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. UK Trial registration ISRCTN78863629 Keywords: Probiotic, Functional food, IBS, RCT Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. A multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS - Constipation or IBS - Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life. 179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12. Significant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. BACKGROUNDIrritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing probiotics improve gastrointestinal transit, however, data are limited by short follow-up periods and evaluation in selected populations. METHODSA multi-centre, randomized, double blind, controlled trial to evaluate the effect of a probiotic vs non-probiotic dairy product on symptoms in IBS with a constipation element (IBS-Constipation or IBS-Mixed profile). Set in 13 general practices within central England. Individuals meeting the ROME III criteria for IBS, aged 18-65 completed a pre-study diary. Eligible individuals were randomized to consume dairy 'yoghurt' products which either did or did not contain active probiotics twice daily and to complete a daily diary. Primary outcome was subjective global assessment of symptom relief at week 4. Other outcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, ease of bowel movement and quality of life. RESULTS179 were randomized (91 active, 88 placebo). 76 (43 active, 33 placebo) completed the study. No significant between group differences existed at 4 weeks (57% active vs 53% placebo, reported adequate relief (p = 0.71)). By week 8, 46% active vs 68% placebo reported adequate relief (p = 0.03). This was sustained at week 12. CONCLUSIONSSignificant improvements were reported for most outcomes in all trial participants but improvement did not differ by group. This trial does not provide evidence for effectiveness of a probiotic in IBS, in variance with a body of published literature and review conclusions. Differential drop out may however cloud interpretation of data. UK TRIAL REGISTRATION: ISRCTN78863629. |
| ArticleNumber | 45 |
| Audience | Academic |
| Author | Hobbs, F D Richard Holder, Roger McCahon, Deborah Wilson, Sue Roberts, Lesley M |
| AuthorAffiliation | 2 Department of Primary Care Health Sciences, Oxford University, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET, UK 1 Primary Care Clinical Sciences, School of Health and Population Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK |
| AuthorAffiliation_xml | – name: 1 Primary Care Clinical Sciences, School of Health and Population Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK – name: 2 Department of Primary Care Health Sciences, Oxford University, 2nd Floor, 23-38 Hythe Bridge Street, Oxford OX1 2ET, UK |
| Author_xml | – sequence: 1 givenname: Lesley M surname: Roberts fullname: Roberts, Lesley M organization: Primary Care Clinical Sciences, School of Health and Population Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK – sequence: 2 givenname: Deborah surname: McCahon fullname: McCahon, Deborah – sequence: 3 givenname: Roger surname: Holder fullname: Holder, Roger – sequence: 4 givenname: Sue surname: Wilson fullname: Wilson, Sue – sequence: 5 givenname: F D Richard surname: Hobbs fullname: Hobbs, F D Richard |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23496803$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkstv1DAQxi1URB9w5oYscWgvaf1MnAvSUpWHVIkLSNwsx3a2rhzP4iSg_vc4bFm6qEjIBz_mN5_Hn-cYHSRIHqGXlJxTquoLKhpaMU6-VpRXQj5BR7uTgwfrQ3Q8jreE0EYx_gwdMi7aWhF-hOIKZ5McDGH0DltIU4YYy3LKwUQMPTZ4k6ELMAWLT_s52SlAKqEewJ3ikPB04_Fgkln7wadpSQk5h8l00eMOfviIx7vkMgz-OXramzj6F_fzCfry7urz5Yfq-tP7j5er66qTikyVIVJa5WrfMm-ZVIz4ntKmbqWhzDimaN06IrqWCm6MaIyoy8Zx5lrVEGr5CXqz1d3M3eCdLWVlE_Umh8HkOw0m6P1ICjd6Dd81r4nkjBSBt1uB8u5_COxHLAx6cVsvbmvKtZBF5Oy-igzfZj9OuphsfYwmeZjHQgklFGNU_QdKW6oYFXVBX_-F3sKcy4f8opRkRAj-h1qb6HVIPZQy7SKqV5ILqWTLlmvPH6HKcH4IpRd8H8r5XsLFNsFmGMfs-50llOilIR8x4dXDr9jxvzuQ_wTQ5txH |
| CitedBy_id | crossref_primary_10_1016_j_jff_2016_04_031 crossref_primary_10_3389_fphar_2022_853011 crossref_primary_10_1016_j_ijsu_2020_01_142 crossref_primary_10_1053_j_gastro_2020_05_060 crossref_primary_10_1186_s12876_018_0788_9 crossref_primary_10_1016_j_clnesp_2024_02_025 crossref_primary_10_3748_wjg_v21_i24_7362 crossref_primary_10_3390_biom11081154 crossref_primary_10_1016_j_clnu_2023_03_021 crossref_primary_10_3390_foods11172691 crossref_primary_10_2169_naika_108_22 crossref_primary_10_3390_nu15173856 crossref_primary_10_1186_s12876_016_0470_z crossref_primary_10_1097_MEG_0000000000000484 crossref_primary_10_1186_1471_230X_14_171 crossref_primary_10_4240_wjgs_v13_i9_923 crossref_primary_10_1093_jn_nxab019 crossref_primary_10_5056_jnm15171 crossref_primary_10_1111_jhn_12386 crossref_primary_10_1111_jhn_12385 crossref_primary_10_3748_wjg_v22_i7_2219 crossref_primary_10_1111_nmo_13037 crossref_primary_10_1016_j_ijsu_2020_04_063 crossref_primary_10_1097_JS9_0000000000000658 crossref_primary_10_3748_wjg_v22_i32_7186 crossref_primary_10_3390_nu15163504 crossref_primary_10_1192_bja_2017_34 crossref_primary_10_26442_26586630_2023_4_202543 crossref_primary_10_1007_s10620_018_5139_8 crossref_primary_10_1016_j_gtc_2017_09_011 crossref_primary_10_1038_ajg_2014_187 crossref_primary_10_1038_s41395_018_0084_x crossref_primary_10_21518_2079_701X_2018_14_98_108 crossref_primary_10_3748_wjg_v26_i41_6488 crossref_primary_10_1007_s10096_017_3060_2 crossref_primary_10_1111_apt_15001 crossref_primary_10_3389_fcimb_2022_859967 crossref_primary_10_1007_s40265_014_0292_7 crossref_primary_10_3168_jds_2015_10743 crossref_primary_10_5817_CSF2023_5_233 crossref_primary_10_3389_fphar_2020_00332 crossref_primary_10_1038_s41598_020_75225_z crossref_primary_10_5056_jnm16001 crossref_primary_10_1016_j_clnu_2022_07_003 crossref_primary_10_1099_jmm_0_001758 crossref_primary_10_5056_jnm15071 crossref_primary_10_3390_nu16132114 crossref_primary_10_1007_s10787_014_0201_4 crossref_primary_10_1007_s40139_018_0160_3 crossref_primary_10_1097_MD_0000000000016068 crossref_primary_10_1007_s12325_016_0336_3 crossref_primary_10_4103_sjg_SJG_384_19 crossref_primary_10_1038_ajg_2014_202 crossref_primary_10_1093_nutrit_nuaa013 crossref_primary_10_3390_nu15163526 crossref_primary_10_3748_wjg_v21_i10_3072 crossref_primary_10_1016_j_bpg_2016_01_003 |
| Cites_doi | 10.1136/gut.46.1.78 10.1053/j.gastro.2005.11.058 10.1046/j.1365-2036.2003.01456.x 10.1023/A:1018831127942 10.1136/bmj.39196.666377.BE 10.1017/S1463423610000095 10.1097/01.mcg.0000165649.32371.71 10.12938/bifidus1996.20.43 10.1111/j.1365-2036.2007.03362.x 10.1016/0016-5085(95)90373-9 10.1007/BF01303162 10.1111/j.1572-0241.2006.00734.x 10.1080/089106001753341291 10.1046/j.1365-2036.1997.142318000.x 10.1186/1471-230X-8-30 10.1079/BJN2002631 10.1016/j.gtc.2010.12.009 10.1186/1471-230X-9-15 10.1111/j.1365-2036.2006.02839.x 10.1186/1472-6882-8-65 10.1099/mic.0.043257-0 10.1016/j.gtc.2005.05.008 10.1016/0016-5085(95)90738-6 10.1097/00004836-200307000-00029 10.1080/08910600310015565 10.1097/00004836-200603000-00020 10.1097/01.mcg.0000156104.67505.5b 10.1055/s-2004-813934 10.1093/gerona/50A.4.M184 10.1017/S0007114509990882 10.1007/s11894-006-0053-1 10.1046/j.1365-2036.2002.01188.x 10.1136/bmj.304.6819.87 10.1111/j.1365-2036.2008.03853.x 10.3748/wjg.v12.i18.2830 10.1111/j.1365-2982.2006.00879.x 10.1136/gut.43.6.770 10.1136/gut.2008.167270 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2013 BioMed Central Ltd. 2013 Roberts et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2013 Roberts et al.; licensee BioMed Central Ltd. 2013 Roberts et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2013 BioMed Central Ltd. – notice: 2013 Roberts et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2013 Roberts et al.; licensee BioMed Central Ltd. 2013 Roberts et al.; licensee BioMed Central Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QP 7QR 7T5 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH H94 K9. M0S M1P P64 PIMPY PQEST PQQKQ PQUKI PRINS 7X8 7QL 7T7 C1K 5PM |
| DOI | 10.1186/1471-230X-13-45 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biotechnology and BioEngineering Abstracts Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Environmental Sciences and Pollution Management PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Central (Alumni) MEDLINE - Academic Industrial and Applied Microbiology Abstracts (Microbiology A) Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE Engineering Research Database Publicly Available Content Database CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-230X |
| EndPage | 45 |
| ExternalDocumentID | oai_biomedcentral_com_1471_230X_13_45 2922904241 A534585928 10_1186_1471_230X_13_45 23496803 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom |
| GeographicLocations_xml | – name: United Kingdom |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7QP 7QR 7T5 7XB 8FD 8FK AZQEC DWQXO FR3 H94 K9. P64 PQEST PQUKI PRINS 7X8 7QL 7T7 C1K ABVAZ AFNRJ 5PM |
| ID | FETCH-LOGICAL-b580t-a055c8d6e92ec25820ef117695a12ad28169d04b9143aa47a464b9d32d98701c3 |
| IEDL.DBID | RBZ |
| ISSN | 1471-230X |
| IngestDate | Tue Sep 17 21:06:37 EDT 2024 Wed May 22 07:14:35 EDT 2024 Fri Oct 25 02:08:44 EDT 2024 Sat Oct 05 04:33:49 EDT 2024 Thu Oct 10 18:57:24 EDT 2024 Wed Aug 14 18:51:22 EDT 2024 Tue Nov 12 23:35:26 EST 2024 Thu Sep 12 17:26:23 EDT 2024 Sat Sep 28 07:51:31 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b580t-a055c8d6e92ec25820ef117695a12ad28169d04b9143aa47a464b9d32d98701c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 ObjectType-Feature-2 |
| OpenAccessLink | http://dx.doi.org/10.1186/1471-230X-13-45 |
| PMID | 23496803 |
| PQID | 1318520443 |
| PQPubID | 44673 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3605320 biomedcentral_primary_oai_biomedcentral_com_1471_230X_13_45 proquest_miscellaneous_1348482218 proquest_miscellaneous_1319182146 proquest_journals_1318520443 gale_infotracmisc_A534585928 gale_infotracacademiconefile_A534585928 crossref_primary_10_1186_1471_230X_13_45 pubmed_primary_23496803 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-03-07 |
| PublicationDateYYYYMMDD | 2013-03-07 |
| PublicationDate_xml | – month: 03 year: 2013 text: 2013-03-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC gastroenterology |
| PublicationTitleAlternate | BMC Gastroenterol |
| PublicationYear | 2013 |
| Publisher | BioMed Central Ltd BioMed Central |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
| References | 19091823 - Gut. 2010 Mar;59(3):325-32 18651941 - BMC Gastroenterol. 2008;8:30 19099570 - BMC Complement Altern Med. 2008;8:65 19622191 - Br J Nutr. 2009 Dec;102(11):1654-62 11876714 - Aliment Pharmacol Ther. 2002 Mar;16(3):587-93 16863564 - Am J Gastroenterol. 2006 Jul;101(7):1581-90 16718806 - World J Gastroenterol. 2006 May 14;12(18):2830-8 19220890 - BMC Gastroenterol. 2009;9:15 17300285 - Neurogastroenterol Motil. 2007 Mar;19(3):166-72 7614239 - J Gerontol A Biol Sci Med Sci. 1995 Jul;50(4):M184-9 12811225 - J Clin Gastroenterol. 2003 Jul;37(1):93-4 9824603 - Gut. 1998 Dec;43(6):770-4 7498636 - Gastroenterology. 1995 Dec;109(6):1736-41 15798491 - J Clin Gastroenterol. 2005 May-Jun;39(5 Suppl 3):S243-6 15942432 - J Clin Gastroenterol. 2005 Jul;39(6):469-84 9512138 - Dig Dis Sci. 1998 Feb;43(2):400-11 1737146 - BMJ. 1992 Jan 11;304(6819):87-90 15871070 - Z Gastroenterol. 2005 May;43(5):467-71 16836944 - Curr Gastroenterol Rep. 2006 Aug;8(4):321-6 21426615 - Prim Health Care Res Dev. 2011 Jan;12(1):52-67 21333908 - Gastroenterol Clin North Am. 2011 Mar;40(1):207-22 15239910 - Br J Gen Pract. 2004 Jul;54(504):495-502 12215182 - Br J Nutr. 2002 Sep;88 Suppl 1:S67-72 17510152 - BMJ. 2007 May 19;334(7602):1037-9 17635382 - Aliment Pharmacol Ther. 2007 Aug 1;26(3):475-86 20705664 - Microbiology. 2010 Nov;156(Pt 11):3205-15 16084312 - Gastroenterol Clin North Am. 2005 Sep;34(3):533-45, x 7657095 - Gastroenterology. 1995 Sep;109(3):671-80 10601059 - Gut. 2000 Jan;46(1):78-82 12641512 - Aliment Pharmacol Ther. 2003 Mar 1;17(5):643-50 8359066 - Dig Dis Sci. 1993 Sep;38(9):1569-80 9146781 - Aliment Pharmacol Ther. 1997 Apr;11(2):395-402 18801055 - Aliment Pharmacol Ther. 2009 Jan;29(1):104-14 16573790 - Aliment Pharmacol Ther. 2006 Apr 1;23(7):879-81 16633134 - J Clin Gastroenterol. 2006 Mar;40(3):264-9 16678567 - Gastroenterology. 2006 Apr;130(5):1538-51 JA Madden (906_CR39) 2002; 88 R Farndale (906_CR12) 2011; 12 EM Quigley (906_CR16) 2011; 40 EM Quigley (906_CR41) 2005; 34 EJ Irvine (906_CR29) 2006; 130 D Guyonnet (906_CR25) 2007; 26 DL Patrick (906_CR32) 1998; 43 S Wilson (906_CR6) 2004; 54 NJ Talley (906_CR2) 1995; 109 MH Floch (906_CR20) 2005; 39 R Jones (906_CR9) 1992; 304 S Méance (906_CR35) 2003; 15 A Roalfe (906_CR31) 2008; 8 S Méance (906_CR34) 2001; 13 P Moayyedi (906_CR17) 2010; 59 D Guyonnet (906_CR23) 2009; 102 AW Mangel (906_CR30) 2006; 23 AP Hungin (906_CR8) 2003; 17 M Bouvier (906_CR36) 2001; 20 I Posserud (906_CR10) 2006; 12 DA Drossman (906_CR27) 2006 N Hoveyda (906_CR18) 2009; 9 CY Francis (906_CR28) 1997; 11 DC Montrose (906_CR19) 2005; 39 WG Thompson (906_CR4) 2000; 46 A Agrawal (906_CR24) 2009; 29 P Young (906_CR22) 2006; 8 EA O'Keefe (906_CR11) 1995; 50 TM Kennedy (906_CR3) 1998; 43 PJ Whorwell (906_CR33) 2006; 101 P Marteau (906_CR26) 2002; 16 EM Quigley (906_CR40) 2007; 19 SM Faber (906_CR38) 2003; 37 L Agreus (906_CR5) 1995; 109 M Camilleri (906_CR37) 2006; 40 N de Jong (906_CR1) 2007; 334 A Salonen (906_CR15) 2010; 156 HJ Krammer (906_CR21) 2005; 43 DA Drossman (906_CR7) 1993; 38 Leatherhead Food International (906_CR14) 2006 LR Harris (906_CR13) 2008; 8 |
| References_xml | – volume: 46 start-page: 78 issue: 1 year: 2000 ident: 906_CR4 publication-title: Gut doi: 10.1136/gut.46.1.78 contributor: fullname: WG Thompson – volume: 130 start-page: 1538 issue: 5 year: 2006 ident: 906_CR29 publication-title: Gastroenterology doi: 10.1053/j.gastro.2005.11.058 contributor: fullname: EJ Irvine – volume: 17 start-page: 643 issue: 5 year: 2003 ident: 906_CR8 publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.2003.01456.x contributor: fullname: AP Hungin – volume: 43 start-page: 400 issue: 2 year: 1998 ident: 906_CR32 publication-title: Dig Dis Sci doi: 10.1023/A:1018831127942 contributor: fullname: DL Patrick – volume: 334 start-page: 1037 issue: 7602 year: 2007 ident: 906_CR1 publication-title: BMJ doi: 10.1136/bmj.39196.666377.BE contributor: fullname: N de Jong – volume: 12 start-page: 52 year: 2011 ident: 906_CR12 publication-title: Primary Health Care Research & Development doi: 10.1017/S1463423610000095 contributor: fullname: R Farndale – volume: 39 start-page: 469 issue: 6 year: 2005 ident: 906_CR19 publication-title: J Clin Gastroenterol doi: 10.1097/01.mcg.0000165649.32371.71 contributor: fullname: DC Montrose – volume: 20 start-page: 43 year: 2001 ident: 906_CR36 publication-title: Bioscience Microflora doi: 10.12938/bifidus1996.20.43 contributor: fullname: M Bouvier – volume: 26 start-page: 475 year: 2007 ident: 906_CR25 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2007.03362.x contributor: fullname: D Guyonnet – volume: 109 start-page: 671 issue: 3 year: 1995 ident: 906_CR5 publication-title: Gastroenterology doi: 10.1016/0016-5085(95)90373-9 contributor: fullname: L Agreus – volume: 38 start-page: 1569 issue: 9 year: 1993 ident: 906_CR7 publication-title: Dig Dis Sci doi: 10.1007/BF01303162 contributor: fullname: DA Drossman – volume: 101 start-page: 1581 year: 2006 ident: 906_CR33 publication-title: Am J Gstroenterol doi: 10.1111/j.1572-0241.2006.00734.x contributor: fullname: PJ Whorwell – volume: 13 start-page: 217 year: 2001 ident: 906_CR34 publication-title: Microb Ecol Health Dis doi: 10.1080/089106001753341291 contributor: fullname: S Méance – volume: 11 start-page: 395 issue: 2 year: 1997 ident: 906_CR28 publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.1997.142318000.x contributor: fullname: CY Francis – volume: 8 start-page: 30 year: 2008 ident: 906_CR31 publication-title: BMC Gastroenterol doi: 10.1186/1471-230X-8-30 contributor: fullname: A Roalfe – volume: 88 start-page: S67 issue: Suppl 1 year: 2002 ident: 906_CR39 publication-title: Br J Nutr doi: 10.1079/BJN2002631 contributor: fullname: JA Madden – volume: 40 start-page: 207 year: 2011 ident: 906_CR16 publication-title: Gastroenterol Clin North Am doi: 10.1016/j.gtc.2010.12.009 contributor: fullname: EM Quigley – volume: 9 start-page: 15 year: 2009 ident: 906_CR18 publication-title: BMC Gastroenterol doi: 10.1186/1471-230X-9-15 contributor: fullname: N Hoveyda – volume: 23 start-page: 879 issue: 7 year: 2006 ident: 906_CR30 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2006.02839.x contributor: fullname: AW Mangel – volume: 8 start-page: 65 year: 2008 ident: 906_CR13 publication-title: BMC Complement Altern Med doi: 10.1186/1472-6882-8-65 contributor: fullname: LR Harris – volume: 156 start-page: 3205 year: 2010 ident: 906_CR15 publication-title: Microbiology doi: 10.1099/mic.0.043257-0 contributor: fullname: A Salonen – volume: 34 start-page: 533 issue: 3 year: 2005 ident: 906_CR41 publication-title: Gastroenterol Clin North Am doi: 10.1016/j.gtc.2005.05.008 contributor: fullname: EM Quigley – volume: 109 start-page: 1736 issue: 6 year: 1995 ident: 906_CR2 publication-title: Gastroenterology doi: 10.1016/0016-5085(95)90738-6 contributor: fullname: NJ Talley – volume: 37 start-page: 93 issue: 1 year: 2003 ident: 906_CR38 publication-title: J Clin Gastroenterol doi: 10.1097/00004836-200307000-00029 contributor: fullname: SM Faber – volume-title: Rome III. The functional gastrointestinal disorders year: 2006 ident: 906_CR27 contributor: fullname: DA Drossman – volume: 15 start-page: 15 year: 2003 ident: 906_CR35 publication-title: Microb Ecol Health Dis doi: 10.1080/08910600310015565 contributor: fullname: S Méance – volume: 40 start-page: 264 issue: 3 year: 2006 ident: 906_CR37 publication-title: J Clin Gastroenterol doi: 10.1097/00004836-200603000-00020 contributor: fullname: M Camilleri – volume: 39 start-page: S243 issue: 5 Suppl year: 2005 ident: 906_CR20 publication-title: J Clin Gastroenterol doi: 10.1097/01.mcg.0000156104.67505.5b contributor: fullname: MH Floch – volume: 43 start-page: 467 issue: 5 year: 2005 ident: 906_CR21 publication-title: Z Gastroenterol doi: 10.1055/s-2004-813934 contributor: fullname: HJ Krammer – volume: 50 start-page: M184 issue: 4 year: 1995 ident: 906_CR11 publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/50A.4.M184 contributor: fullname: EA O'Keefe – volume: 102 start-page: 1654 year: 2009 ident: 906_CR23 publication-title: Br J Nut doi: 10.1017/S0007114509990882 contributor: fullname: D Guyonnet – volume-title: The international market for functional foods. Market report leaflet year: 2006 ident: 906_CR14 contributor: fullname: Leatherhead Food International – volume: 54 start-page: 495 issue: 504 year: 2004 ident: 906_CR6 publication-title: Br J Gen Pract contributor: fullname: S Wilson – volume: 8 start-page: 321 issue: 4 year: 2006 ident: 906_CR22 publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-006-0053-1 contributor: fullname: P Young – volume: 16 start-page: 587 issue: 3 year: 2002 ident: 906_CR26 publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.2002.01188.x contributor: fullname: P Marteau – volume: 304 start-page: 87 issue: 6819 year: 1992 ident: 906_CR9 publication-title: BMJ doi: 10.1136/bmj.304.6819.87 contributor: fullname: R Jones – volume: 29 start-page: 104 year: 2009 ident: 906_CR24 publication-title: Aliment Pharmacol Ther doi: 10.1111/j.1365-2036.2008.03853.x contributor: fullname: A Agrawal – volume: 12 start-page: 2830 issue: 18 year: 2006 ident: 906_CR10 publication-title: World J Gastroenterol doi: 10.3748/wjg.v12.i18.2830 contributor: fullname: I Posserud – volume: 19 start-page: 166 issue: 3 year: 2007 ident: 906_CR40 publication-title: Neurogastroenterol Motil doi: 10.1111/j.1365-2982.2006.00879.x contributor: fullname: EM Quigley – volume: 43 start-page: 770 issue: 6 year: 1998 ident: 906_CR3 publication-title: Gut doi: 10.1136/gut.43.6.770 contributor: fullname: TM Kennedy – volume: 59 start-page: 325 year: 2010 ident: 906_CR17 publication-title: Gut doi: 10.1136/gut.2008.167270 contributor: fullname: P Moayyedi |
| SSID | ssj0017823 |
| Score | 2.3219695 |
| Snippet | Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods containing... Abstract Background Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests... Background Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods... Doc number: 45 Abstract Background: Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence... BACKGROUNDIrritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods... Background: Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods... BACKGROUND: Irritable Bowel Syndrome (IBS) is a common condition characterised by pain, distension and altered bowel habit. Evidence suggests functional foods... |
| SourceID | pubmedcentral biomedcentral proquest gale crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 45 |
| SubjectTerms | Adult Constipation - epidemiology Constipation - etiology Diet therapy Double-Blind Method Family medicine Female Functional foods Gastroenterology Health aspects Humans Incidence Irritable bowel syndrome Irritable Bowel Syndrome - complications Irritable Bowel Syndrome - diet therapy Male Mediation Methods Middle Aged Patient outcomes Probiotics Probiotics - therapeutic use Quality of Life Treatment Outcome |
| SummonAdditionalLinks | – databaseName: PubMed Central (Open access) dbid: RPM link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LatwwUCQ5lF5K33WbFhUK7UVZS5ZkiZ6W0BAKW3poYG9G1oMueO0l2dBrPqP9vXxJR1p7iVrooeCDjUYPa2Y0I2keCL0L2vHSeEVCbRjhrQgElCNPjJQ8Ofm0Lvo7L77I8wv-eSmWB0hMvjDJaN-2q5O-W5_0q-_JtnKztrPJTmz2dXFayZTPYHaIDoFApy36eHUAIq8aY_hQJWcUVl8CevaS0IrwmKiGxRjpKmbJylzcu0wy_bk-3xFQufHkHWl09hA9GNVIPN8N9xE68P1jdG8xXpQ_QZs5BiHkBsCid3i0R-_gNWXpwEPABm9SCCZoAN_e_IzybXcsiMMwuNubX3jVY9AO8XpvIBOrrS7jaULbedwOP3yHp4gHT9HF2advp-dkTK5AWqHKLTGlEFY56TXzlglQBHygtJZaGMqMY4pK7UrealCojOG14RI-XMWcBhantnqGjvqh9y8QdtwG72hQrHWcawXQVnheM1sHqgIv0MdsopvNLpBGE0Nb5yXAZU3EWBMx1tCq4aJAHya07CumnYuSf4O-j2hrIm9Cc9aMLgYwzBjlqpmLCghQaKYKdJxBAjZsXjwhvhl5-gq6iI7mJedVgd7ui2PNaKfW--E6wWjYsYH4-RcMVxz0MgrdPN_R0v7HJtosUJ1RWTZleQkwSYoKPjLFy_-u-QrdZynXBzz1MTraXl7716Bxbds3icN-A8SQLyQ priority: 500 providerName: National Library of Medicine – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxQxFA66BfFFvLtaJYKwvoROMkkmwQdZpaUILSIW9i1kJgkujDNru8W_70k2OzYKhXmYISeXyZfknCTngtC7oB2vrFckNJYR3opAQDjyxErJk5FP66K989m5PL3gX1ZilQ_crrJa5X5NTAu1G7t4Rn5Ek5lvxXn9cfOLxKhR8XY1h9C4iw4Y7BSqGTr4dHz-9dt0jwD8r84OfaiSRxSWYgJC94rQmkQLpsLIvS94078r9A0WVapP3uBHJw_RgyxI4uUO-Ufojh8eo3tn-ar8CeqXGNiQGwFH73DWSO_hNcXpwGPAFm-SEyYoAC8if9sdC-Iwjm6B1wMG2RD_nNRjYpb1ZTxLaHuP2_G37_He38FTdHFy_P3zKcmhFUgrVLUlthKiU056zXzHBIgBPlDaSC0sZdYxRaV2FW81iFPW8sZyCR-uZk7DBKdd_QzNhnHwLxB2vAve0aBY6zjXCqg74XnDuiZQFfgcfSg62Wx2bjRMdGxdpgDeJkJkIkSG1oaLOXq_h2TKmPYtSv5PuoiQmTgzobjOZgMDaGb0cWWWoobhJzRTc3RYUAISXZm8B93kGX1l_o6_OXo7JcecUUtt8ON1otGwXwPmcxsNVxykMgrVPN-No-nHWPTeryqooSlGWNFlZcqw_pF8gtcyhfh4eXvTX6H7LIXzgKc5RLPt5bV_DULVtn2TZ84fE9sj4Q priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1di9QwMOgJ4ov47eopEYT1JdqkkzRBRBbxOITzyYV9C2mT4EJtz3UP9d87ybZ71_PwRehDSyZJm5npzCTzQcjLaDwULmgWKycY1DIyVI4Cc0pBDvKpfYp3PvmsjpfwaSVX5-WAhgX8caVpl-pJLTft61_ff79Hhn-XGV6rNxx_sAxV6RXjJQN5ndwQgGZ68uOD8yMFFIXZ234EHvL8XDHApdj3diKyLv-4L0iuqVflBTF1dIfcHvRLutgRxF1yLXT3yM2T4QT9PmkXFKWT7xG9wdPBUb3F21y-g_aROnqaczPhAHSexN5ut5DGvvdzuu4oqoz0295rJnVZb9IWQ90GWvc_Q0vHNAgPyPLo45cPx2youMBqqYstc4WUjfYqGBEaIVE7CJHzShnpuHBeaK6ML6A2qGU5B5UDhQ--FN4g3_OmfEgOur4Ljwn10MTgedSi9gBGI3QjA1SiqSLXEWbk7WSR7ekuu4ZN-a6nLch6NqHIJhRZXlqQM_JqRMm-YzZntPobdJ5QZhMJ4XCNG-IO8DVT6iu7kCVSpTRCz8jhBBIx0UybR6TbkU5xihR9XgCUM_Ji35x6Jue1LvRnGcagGYcy6V8woAGVNY7TPNrR0f7DRErqrwucoZpQ2GTJpi3d-mtOFV6qXPnjyX8t9lNyS-QiIHhVh-RguzkLz1AV29bPM4v9AWcSMxM priority: 102 providerName: Scholars Portal |
| Title | A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23496803 https://www.proquest.com/docview/1318520443 https://search.proquest.com/docview/1319182146 https://search.proquest.com/docview/1348482218 http://dx.doi.org/10.1186/1471-230X-13-45 https://pubmed.ncbi.nlm.nih.gov/PMC3605320 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEA_eHYgv4rerZ4kgrC_BJp18FJ_25I5D2EPEg8WXkjYJLtT2OPfw33eS7dbrKr4IpbRkkrSZTGaSzPxCyJtQOsitNyxoKxjUMjA0jjyzSkEK8qldjHdeXqjzS_i4kqvfYNF7O_jcqHcch0-GhvKK8YKBPCBHIiKqxIn5yddxwwAVXfKl3xEPKD5_KWAvsr2dKKT9YfmWXpr6TN5SQmcPyP3BeqSLLbsfkju-e0TuLof98cekXVDUPa5H5nlHBzf0Fh_T4Ry0D9TSq4S8hAXQeVRq27VAGvrezem6o2gQ0u-jT0zMsr6OCwh162nd__Qt3YEcPCGXZ6dfPpyz4TwFVkuTb5jNpWyMU74UvhESdb8PnGtVSsuFdcJwVboc6hJtKGtBW1D44grhSpRq3hRPyWHXd_45oQ6a4B0PRtQOoDRI3UgPWjQ6cBNgRt5PGrm62mJnVBHNepqCglVFFlWRRRUvKpAz8nbHkjFjmqwY9SfpPLKsiuKIxTV2iCrAz4zAVtVCFtjnZCnMjBxPKJETzTR5x_RqEOMfWEWMLc8Bihl5PSbHnNE1rfP9TaIpcZKGGudfNGAATTGO1Tzb9qPxx0SE7Dc51qAnPWzSZNOUbv0tAYEXKp3r8eK_GvsluSfSER946WNyuLm-8a_Q0NrUGTnQK52Ro5PTi0-fs7RcgfclmCwJX5bWxn4BXRwq8w |
| link.rule.ids | 108,230,315,730,783,787,867,888,2228,12068,21400,24330,24949,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,76140,76141 |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA_agvoiftbTqhGE8yV0k02yWXyQU1pO7R0iLdxbyG4SPFh3z_aK_76TXO5sFAr7sEsm-_VLMpNk5jcIvfW15YVxivjKMMIb4QkYR44YKXkM8mlsiHeezeX0nH9ZiEVacLtMbpXbMTEO1HZowxr5EY1hvgXn5YfVLxKyRoXd1ZRC4zbaD1RVMPna_3g8__Z9t48A-q9MhD5UySMKQzEBo3tBaElCBFMW5N5luunfEfqaisrdJ6_po5MH6H4yJPFkg_xDdMv1j9CdWdoqf4y6CQY1ZAfA0VmcPNI7OI15OvDgscGrSMIEN8DjoN82y4LYD4Md42WPwTbEP3fuMaHK8iKsJTSdw83w23V4y3fwBJ2fHJ99mpKUWoE0QhVrYgohWmWlq5lrmQAzwHlKK1kLQ5mxTFFZ24I3NZhTxvDKcAkXtmS2hg5O2_Ip2uuH3j1D2PLWO0u9Yo3lvFYg3QrHK9ZWnirPR-h99pP1akOjoQOxdV4CeOsAkQ4QaVpqLkbo3RaSXcU4b1Hyf9FxgEyHngm3a00KMIDXDBxXeiJKaH6iZmqEDjNJQKLNi7eg69SjL_Xf9jdCb3bFoWbwUuvdcBVlapivgfK5SYYrDlYZhcccbNrR7sNYYO9XBTyhylpY9svykn75I3KClzKm-Hh-86u_RnenZ7NTffp5_vUFusdiag84qkO0t764ci_BwFo3r1Iv-gMW1ibb |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKkSouiHe3LWAkpOViGju244jT8liVRwtCVFpxsZzYhhVpslq24u8zdh7aFMQFKYdEHse7nhnP2Jn5BqGnPrc8MU4RnxlGeCE8AefIESMlj0k-hQ35zqdn8uScv1uIxQ762OfCFBflNwOb_CYgUq7jyfLz7UT0Kq7ecFP-OF5Z3yq9kscUFlkC7vSC0JRwcQ1dh_05D7UcPr_8OnxWAHMYI-574g7r5y8vuJL_Xo3M1tXFe8t6jSMrt0zV_Ba62fmYeNYKxW204-o7aO-0-4p-F1UzDBbKNsBiZ3EXrF7BbSzhgRuPDV5FfCZ4AZ4G09eeGGLfNHaKlzUGtxFfDJEzoctyHY4ZisrhovnlKtxDIdxD5_M3X16dkK7qAimESjbEJEKUykqXM1cyAR6C85RmMheGMmOZojK3CS9y8LSM4ZnhEh5symwOuk_L9D7arZva7SNseemdpV6xwnKeK6AuheMZKzNPlecT9GI0yXrVImzogHk9bgGu68AiHVikaaq5mKBnPUuGjnFLo-SfpNPAMh2UNsiO6XIP4GcG-Cs9EylIpsiZmqCjESVwohw390zXnbL_hCFCBnrCeTpBT4bm0DMEsNWuuYw0OWzlwC79i4YrDg4bhWEetHI0_DEWgP1VAiNkIwkbTdm4pV5-j3DhqYzVPw7-a7Ifo71Pr-f6w9uz94foBos1QeDKjtDuZn3pHoJntikeRW37DZ5FN58 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomised+controlled+trial+of+a+probiotic+%27functional+food%27+in+the+management+of+irritable+bowel+syndrome&rft.jtitle=BMC+gastroenterology&rft.au=Roberts%2C+Lesley&rft.au=McCahon%2C+Deborah&rft.au=Holder%2C+Roger&rft.au=Wilson%2C+Sue&rft.date=2013-03-07&rft.pub=BioMed+Central+Ltd&rft.issn=1471-230X&rft.eissn=1471-230X&rft.volume=13&rft.issue=1&rft.spage=45&rft.epage=45&rft_id=info:doi/10.1186%2F1471-230X-13-45&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_1471_230X_13_45 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-230X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-230X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-230X&client=summon |